Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate

Subscribe to Selected New Research on Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate

46 relevant articles (1 outcomes, 12 trials/studies) found for this Bio-Agent

Description: the type b capsular polysaccharide of HIB-vaccine is chemically combined with the diphtheria toxoid

Also Known As:

Dpo 20 vaccine; Haemophilus influenzae b oligosaccharide vaccine-diphtheria toxoid conjugate; Hib-PS-DT vaccine; Hib-PS-diphtheria toxoid conjugate vaccine; PRP-D; Prohibit

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 314

Biological Products

Vaccines: 15360

Toxoids: 789

Diphtheria Toxoid: 321

Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate: 46

Bacterial Vaccines: 332

Haemophilus Vaccines: 24

Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate: 46

Experts

1.	Jeffrey, M: 2 articles (06/2008 - 02/2006)
2.	González, L: 2 articles (06/2008 - 02/2006)
3.	Martin, S: 2 articles (06/2008 - 02/2006)
4.	Finlayson, J: 1 article (06/2008)
5.	McGovern, G: 1 article (06/2008)
6.	Steele, P: 1 article (06/2008)
7.	Chianini, F: 1 article (06/2008)
8.	Sisó, S: 1 article (06/2008)
9.	Foster, J: 1 article (02/2006)
10.	Langeveld, J P M: 1 article (02/2006)

Related Diseases

1.	Infection 05/01/1992 - "We conclude that for children ages 18 to 60 months a single dose of the Hib conjugate vaccine, PRP-D, is protective against invasive Hib infections. " 11/01/2009 - "As determined by immunohistochemical (IHC) examinations with Bar224 PrP antibody, the prevalence of preclinical infection was very high (72/200; 36.0%), with most infected animals being positive for PrP(d) in lymphoreticular system (LRS) tissues (68/72; 94.4%) compared to those that were positive in brain samples (38/72; 52.8%). " 06/01/2009 - "RESULTS: Initial PrP(d) accumulation consistently occurred in the dorsal motor nucleus of the vagus nerve followed by the hypothalamus, regardless of the breed of sheep, PrP genotype, TSE source and, notably, route of infection; these factors did not appear to affect the topographical progression of PrP(d) deposition in the brain either. " 06/01/2009 - "HYPOTHESIS AND AIM: If direct ENS invasion following oral infection results in an early and specific brain targeting for PrP(d) accumulation, such topographical distribution could be different when other routes of infection were used, highlighting distinct routes for neuroinvasion. " 07/15/2006 - "We demonstrate that blood can become infectious at early stages of ovine BSE infection and that the PrP(d) immunohistochemical phenotype is maintained after transfusion. " Order ALL the reference details at left...
2.	Scrapie 03/01/2009 - "To investigate the potential role of lymphoid tissue nerves in neuroinvasion, we used immunohistochemical methods to study the frequency and distribution of nerves and PrP(d) accumulation in Peyer's patches and other lymphoid tissues from scrapie-affected and unaffected sheep. " 03/01/2009 - "This study compares the WB and IHC characteristics of PrP(d) from brains of primary, secondary and tertiary experimental ovine BSE cases with those of cattle BSE and natural sheep scrapie. " 03/01/2008 - "In biopsy samples, PrP(d) could be demonstrated by immunohistochemical (IHC) and Western immunoblotting methods, and the purpose of the present study was to optimize and evaluate a "rapid test" for the diagnosis of scrapie in rectal biopsy samples. " 05/01/2004 - "The present study examined the relationship between the type of PrP(d) deposits seen by light microscopy and ultrastructural changes in the olivary nuclei and the dorsal motor nucleus of the vagus (DMNV) in naturally infected sheep with clinical scrapie. " 05/01/2003 - "In demonstrating that lymphoid nodules in the Peyer's patches of scrapie-affected sheep possess a substantial network of nerve fibres, the present study shows that nodules provide close contact between nerve fibres and cell populations known to contain abundant PrP(d), including follicular dendritic cells and tingible body macrophages, and that gut-associated lymphoid nodules in sheep may represent an important site for neuroinvasion." Order ALL the reference details at left...
3.	Bovine Spongiform Encephalopathy (Mad Cow Disease) 06/01/2009 - "AIMS: This study characterizes the traumatic brain lesions associated with the I/C injection of the bovine spongiform encephalopathy agent in sheep, assesses the relevance of such lesions in the outcome of clinical disease and provides insight into the mechanisms of PrP(d) conversion and amplification following I/C challenge. " 06/01/2009 - "METHODS: To determine the nature of subcellular changes and their association with PrP(d) we perfusion-fixed brains of eight bovine spongiform encephalopathy (BSE)-affected cows and three control cattle for immunogold electron microscopy at two different neuroanatomical sites. " 02/01/2006 - "Immunohistochemical epitope mapping of abnormal PrP accumulations (PrP(d)) in brain can help in characterizing sheep TSE sources or strains and in identifying potential bovine spongiform encephalopathy (BSE) infections of sheep. " 03/01/2005 - "It has previously been reported that disease-associated prion protein (PrP(d)) derived from natural scrapie and from sheep infected experimentally with bovine spongiform encephalopathy (BSE) differed in respect of their immunohistochemical and immunoblotting properties. " 05/01/2003 - "We have now extended those studies to investigate the effect of different PrP antibodies on the PrP(d) profile of scrapie- and bovine spongiform encephalopathy (BSE)-affected sheep. " Order ALL the reference details at left...
4.	Poliomyelitis (Polio) 01/01/1986 - "Following a booster dose of PRP-D at 14-18 months, simultaneously with either MMR, DPT or polio vaccine, all children in these studies developed greater than 1.0 micrograms/ml of antibody. " 07/01/1988 - "In order to test the suitability of simultaneous administration of PRP-D and other vaccines we administered it to 25 infants mixed with diphtheria-tetanus-pertussis vaccine at 3, 4 and 6 months and simultaneously, but in a separate syringe, with inactivated polio vaccine at 12 months. " 09/13/1993 - "The aim of this study was to examine the immunogenicity of a Haemophilus influenzae type b (Hib) vaccine (PRP-D) in Danish children younger than 18 months of age, given at the same time as a diphtheria-, tetanus- and polio-vaccine at the age of five, six and 15 months. " Order ALL the reference details at left...
5.	Diphtheria 09/13/1993 - "The aim of this study was to examine the immunogenicity of a Haemophilus influenzae type b (Hib) vaccine (PRP-D) in Danish children younger than 18 months of age, given at the same time as a diphtheria-, tetanus- and polio-vaccine at the age of five, six and 15 months. " 09/01/1987 - "Haemophilus influenzae vaccine containing polyribosyl ribitol phosphate (PRP) or PRP covalently linked to diphtheria toxoid (PRP-D) was given to 94 healthy infants 17 to 22 months of age at the same time, but not at the same site, as a diphtheria-tetanus-pertussis booster. " 01/01/1992 - "A randomized, controlled comparison was made in 175 healthy 18-month-old children given either diphtheria and tetanus toxoids and pertussis vaccine, adsorbed (DTP) and haemophilus b diphtheria toxoid conjugate vaccine (PRP/D) concurrently at separate sites (66 children) or a new vaccine combining these products (109 children). " 02/01/1992 - "Mean antibody levels after three injections of polyribosylribitol phosphate conjugated with mutant diphtheria protein (PRP-CRM) or polyribosylribitol phosphate conjugated with tetanus toxoid (PRP-T) were 3.08 micrograms/ml and 3.64 micrograms/ml, respectively, significantly higher than those after the use of polyribosylribitol phosphate conjugated with outer-membrane protein of Neisseria meningitidis (PRP-OMP) (1.14 micrograms/ml) or polyribosylribitol phosphate conjugated with diphtheria toxoid (PRP-D) (0.28 microgram/ml). " 11/01/1993 - "The concept of conjugating carbohydrate with a carrier protein increasing immunogenicity of the PRP led to 4 PRP--protein conjugate vaccines: PRP-diphtheria toxoid conjugated vaccine (PRP-D), outer-membrane protein of Neisseria meningitidis conjugated (PRP-OMP), cross-reacting mutant diphtheria protein (PRP-HbOC) and tetanus-Toxoid conjugated vaccine (PRP-T). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antibodies
2.	PrPSc Proteins
3.	Haemophilus influenzae type b polysaccharide vaccine (HIB-vaccine)
4.	Diphtheria Toxoid (Vaccine, Diphtheria)
5.	Conjugate Vaccines
6.	Vaccines
7.	Tetanus Toxoid (Vaccine, Tetanus)
8.	Membrane Proteins (Integral Membrane Proteins)
9.	Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (ActHIB)
10.	Integration Host Factors (Host Factor)

Related Therapies and Procedures

1.	Injections

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>